期刊文献+

非全身肝素化冠状动脉造影安全性的临床评价 被引量:1

Clinical evaluation of the safety of coronary angiography without heparinization
暂未订购
导出
摘要 目的评价非全身肝素化状态下冠状动脉造影(CAG)的安全性。方法 100例择期冠状动脉脉造影的病人随机分为常规肝素抗凝组50例(肝素组)和无肝素抗凝组50例(非肝素组),非肝素组要求从鞘管进入股动脉到CAG结束在10min内完成。观察CAG期间及其后6h内病人发生卒中、新发生的外周动脉血栓、穿刺及非穿刺部位出血并发症情况。结果肝素组术中及术后无卒中、新发生的外周动脉血栓和非穿刺部位出血发生,穿刺部位血肿4例(8.0%);非肝素组术后1例(2.0%)发生短暂性脑缺血发作,无新发生的外周动脉血栓、穿刺和非穿刺部位出血发生。结论对技术熟练的术者,在10min内,非全身肝素化状态下完成从鞘管进入股动脉到CAG操作是安全的,可减少穿刺和非穿刺部位出血并发症的发生。 Objective To evaluate the safety of coronary angiography(CAG) without heparinization. Methods One hundred patients who would accept elective CAG were divided into two groups named heparin group ( CAG with heparinization) and beparin-free group (CAG without heparinization) at random. The precedures were required to be finished within 10 minutes for heparin-free group. Stroke, new thrombus in peripheral artery, the complications of hemorrhage at the artery puncture site and non-puncture site were observed from the time of insetting the sheath into the artery to 6 hours after CAG. Results There were no srtoke, new thrombus in peripheral artery and hemorrhage at the non-puncture site and four patients (8.0%) had the complication of haematoma at the artery puncture sites in heparin group. There were no stroke, new thrombus in peripheral artery and hemorrhage at the artery puncture site and non-puncture site and one patient (2.0%) suffered from transient cerebral ischemia attack in the heparin-free group. Conclusions If the experienced operators can finish the procedures from insetting the sheath into the artery to the end of CAG within 10 minutes, the procedures of CAG without heparinization are safe. CAG without heparinization can decrease the complication of hemorrhage at the artery puncture site and non-puncture site.
出处 《中华老年多器官疾病杂志》 2006年第1期30-32,共3页 Chinese Journal of Multiple Organ Diseases in the Elderly
关键词 血管造影 经腔 经皮冠状动脉 肝素 angiography, transluminal, percutaneous coronary heparin
  • 相关文献

参考文献8

  • 1[1]Vrel D,Grainger RG.Cardiac catheterization and angiocardiography.3rd ed.London:Churchill Livingstone,1978.
  • 2[2]Pujadas G.Coronary angiography.New York:McGraw-Hill,1980.
  • 3[3]Collet J P,Montalescot G,Lison L,et al.Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris.Circulation,2001,103:658-663.
  • 4[4]Kereiakes DJ,Grines C,Fry E,et al.Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.J Invasive Cardiol,2001,13:272-278.
  • 5[5]Choussat R,Montalescot G,Collet J P,et al.A unique,low dose of intravenous enoxaparin in elective percutaneous coronary intervention.J Am Coll Cardiol,2002,40:1943-1950.
  • 6[6]Wells MJ,Blajchman MA.In vivo clearance of ternary complexes of vitronectin thrombin antithrombin is mediated by hepatic heparan sulfate proteoglycans.J Biol Chem,1998,273:23440-23447.
  • 7[7]De Boer HC,Preissner KT,Bouma BN,et al.Internalization of vitronectin thrombin antithrombin complex by endothelial cells leads to deposition of the complex into the subendothelial matrix.J Biol Chem,1995,270:30733-30740.
  • 8[8]Rao AK,Pratt C,Berke A,et al.Thrombolysis in myocardial infarction (TIMI) trial-phase Ⅰ:hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.J Am Coll Cardiol,1988,11:1-11.

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部